Mid Cap
Diagnostics & Research
Stocks Ranked by
Market Capitalization
| Name | Market cap | Price |
Price change % |
|
|---|---|---|---|---|
1
Twist Bioscience
TWST
$9.5B
| $9.5B | $151.42 | 7.54% |
|
2
Qiagen
QGEN
$9.01B
| $9.01B | $43.65 | 4.48% |
|
3
RadNet
RDNT
$6.05B
| $6.05B | $76.86 | 2.91% |
|
4
Sotera Health
SHC
$5.57B
| $5.57B | $19.51 | 1.77% |
|
|
BLLN
5
BillionToOne Inc
BLLN
$4.72B
| $4.72B | $100.08 | 3.45% |
|
6
Adaptive Biotechnologies
ADPT
$4.19B
| $4.19B | $26.25 | 2.74% |
|
|
GRAL
7
GRAIL Inc
GRAL
$3.69B
| $3.69B | $82.54 | 7.78% |
|
8
Veracyte
VCYT
$3.54B
| $3.54B | $44.04 | 6.2% |
|
9
CareDx
CDNA
$2.63B
| $2.63B | $50.80 | 6.95% |
|
10
GeneDx Holdings
WGS
$2.61B
| $2.61B | $87.41 | 2.61% |
|
11
NeoGenomics
NEO
$2.16B
| $2.16B | $16.79 | 2.32% |
|
Mid Cap Diagnostics & Research Stocks at a Glance
Diagnostics and research companies run laboratory testing, imaging, and analytical services, and supply the instruments behind them. Testing volumes are recurring and largely non-discretionary, while research-tools demand follows pharma and academic R&D budgets.
There are 11 mid cap Diagnostics & Research stocks — companies in the Diagnostics & Research industry with a market cap between $2B and $10B — worth a combined $53.7B.
The largest by market cap are Twist Bioscience (TWST) at $9.5B, Qiagen (QGEN) at $9.01B and RadNet (RDNT) at $6.05B.
Among institutional investors, BillionToOne Inc (BLLN) drew the most net new fund positions in Q2 2026: 77 funds opened new positions, taking total fund holders up 66 (73%) quarter-over-quarter.
- Combined market cap: $53.7B across 11 stocks.
- Mid Cap: market cap between $2B and $10B.
- Largest constituent: Twist Bioscience (TWST), $9.5B market cap.
- Most net new fund positions in Q2 2026: BillionToOne Inc (BLLN), +66 holders.
Market caps and prices updated daily; fund activity based on aggregated SEC 13F filings for Q2 2026.